ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1150

Effect of Curcumin on Vascular and Cognitive Function in CKD: A Randomized Controlled Trial

Session Information

  • Late-Breaking Posters
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Gimblet, Colin J., The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Kruse, Nicholas T, Central Michigan University, Mount Pleasant, Michigan, United States
  • Geasland, Katharine M., The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Michelson, Jeni, University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
  • Sun, Mingyao, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Ten Eyck, Patrick, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Sambharia, Meenakshi, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Rossman, Matthew, University of Colorado Boulder, Boulder, Colorado, United States
  • Linkenmeyer, Carinda, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Tamura, Manjula, Stanford University, Stanford, California, United States
  • Chonchol, Michel, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Seals, Douglas R., University of Colorado Boulder, Boulder, Colorado, United States
  • Hoth, Karin, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
  • Jalal, Diana I., The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, United States
Background

Chronic kidney disease (CKD) increases the risk of developing cardiovascular disease (CVD) and cognitive impairment. Curcumin is a polyphenol that has been reported to improve vascular and cognitive function in middle-aged and older adults, however its effects on vascular and cognitive function in patients with CKD are unknown. We hypothesized that 12-month curcumin supplementation would improve vascular and cognitive function in patients with CKD.

Methods

88 adults with CKD (stage 3B or 4) participated in a 12-month, randomized, double-blind, placebo-controlled, parallel-arms intervention to examine the effects of curcumin (Longvida, 2000 mg/day) on vascular and cognitive function. Our primary outcomes were endothelial function and aortic stiffness determined from brachial artery flow-mediated dilation (FMD) and carotid-femoral pulse wave velocity (cfPWV), respectively. Our secondary outcomes were endothelium- independent dilation via nitroglycerin mediated dilation and cognitive function assessed via the NIH Toolbox Cognition Battery.

Results

75% of the participants were male, 56% had diabetes, and 15% had a history of CVD. The mean±SD age and eGFR were 66±8 years and 34.7±10.8 ml/min/1.73m2, respectively. The median (IQR) UACR was 81.9 mg/g (9.7-417.3). Following 12-months of curcumin supplementation, we observed no change in brachial artery FMD, nitroglycerin mediated dilation, or cfPWV (P>0.05; Table 1). Additionally, we observed no change in processing speed, executive function, memory, or language (P>0.05; Table 1). eGFR, UACR, hemoglobin A1c, and blood pressure were unchanged (P>0.05).

Conclusion

12-month curcumin supplementation did not change vascular or cognitive function in patients with CKD.

Change in primary and secondary outcomes according to study group
VariableCurcuminPlaceboP value
FMD, %-0.7 (-2.1,1.1)-0.1 (-1.5,1.5)0.69
cfPWV, m/s0.3±2.40.4±4.20.94
Nitroglycerin dilation, %-1.3±7.7-1.3±6.50.97
Processing speed*-0.9±8.91.8±7.00.15
Executive function*2.6±9.02.3±9.50.86
Memory*2.2±9.22.6±8.50.83
Language*-0.5±5.8-1.3±4.50.51

*Age-adjusted T-score

Funding

  • Other NIH Support